Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACHE | P22303 | 16/20 | 0.51 |
| ▸ | TGFBR1 | P36897 | 4/20 | 0.41 |
| ▸ | BCHE | P06276 | 5/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7575734 | 0.81 | ACHE (0.76) | ACHEBCHE | |
| SCHEMBL6989946 | 0.77 | ACHE (0.67) | ACHEBCHE | |
| Benzene SCHEMBL9411522 | 0.72 | ACHE (0.68) | ACHEBCHE | |
| SCHEMBL6988131 | 0.71 | ACHE (0.69) | ACHEBCHE | |
| SCHEMBL6992136 | 0.67 | ACHE (0.67) | ACHEBCHE | |
| SCHEMBL6985465 | 0.67 | ACHE (0.67) | ACHEBCHE | |
| SCHEMBL27917924 | 0.67 | ALDH1A1 (0.70) | TGFBR1 | |
| SCHEMBL5823779 | 0.67 | ACHE (0.61) | ACHEBCHE | |
| SCHEMBL6988213 | 0.66 | ACHE (0.65) | ACHEBCHE | |
| SCHEMBL6993296 | 0.65 | ACHE (0.75) | ACHEBCHE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6498255-B2 | CHOLINESTERASE INHIBITORS; COGNITION ACTIVATORS; ALZHEIMER'S DISEASE; E.G., 3-(2-(1-(PHENYLMETHYL)-4-PIPERIDINYL)ETHYL)-1,2-BENZISOXAZOLE | PFIZER INC. | 2002-12-24 | — | — | US | disclosed |
| US-20020028834-A1 | Heterocyclic-cyclic amine derivatives | VILLALOBOS ANABELLA (US) | 2002-03-07 | — | — | US | disclosed |
| US-6326382-B1 | CHOLINESTERASE INHIBITORS; USEFUL IN ENHANCING MEMORY IN PATIENTS SUFFERING FROM DEMENTIA AND ALZHEIMER'S DISEASE | EISAI CO., LTD (JP) | 2001-12-04 | — | — | US | disclosed |
| EP-0646115-A1 | HETEROCYCLIC-CYCLIC AMINE DERIVATIVES | Eisai Co., Ltd. (JP) | 1995-04-05 | — | — | EP | disclosed |
| WO-1992017475-A1 | HETEROCYCLIC-CYCLIC AMINE DERIVATIVES | PFIZER INC. (US) | 1992-10-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020028834-A1 | Heterocyclic-cyclic amine derivatives | BCHE, ACHE, CHRM1 | ACHE 2/4885TGFBR1 2304/4885BCHE 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.